The dermatological antifungal segment has three more FDA approved options. This is good news for a specialty area that could use more diversity when it comes to treating fungal infections. Tavaborole and Efinaconazole were both approved by the FDA in 2014 to treat fungi of the nail and nailbeds, and Crisaborole was approved in 2016[…]
3 of the Newest API’s in the Dermatological Antifungal Segment
Anti-Fungal, EU Approved 2014, FDA Approved 2016 Tags: CrisaboroledermatitiseczemaEfinaconazolefungal infectionsPsoriasisTavaborole Jan 16, 2018
Eteplirsen Granted FDA Accelerated Approval
Drug Research & Development API, FDA Accelerated Approval Program, FDA Approved 2016 Tags: DMDDuchenne Muscular DystrophyEteplirsen Sep 20, 2016
The U.S. Food and Drug Administration approved Eteplirsen CAS# 1173755-55-9 (marketed as Exondys 51) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the[…]